Heart Failure with Preserved Ejection Fraction: Molecular Pathways of the Aging Myocardium

Overview

Journal Circ Res

Specialty Cardiology & Vascular Diseases

Date 2014 Jun 22

PMID 24951760

Citations 91

Authors

Francesco S Loffredo

Andriana P Nikolova

James R Pancoast

Richard T Lee

Affiliations

Soon will be listed here.

Abstract

Age-related diastolic dysfunction is a major factor in the epidemic of heart failure. In patients hospitalized with heart failure, HFpEF is now as common as heart failure with reduced ejection fraction. We now have many successful treatments for heart failure with reduced ejection fraction, while specific treatment options for HFpEF patients remain elusive. The lack of treatments for HFpEF reflects our very incomplete understanding of this constellation of diseases. There are many pathophysiological factors in HFpEF, but aging appears to play an important role. Here, we propose that aging of the myocardium is itself a specific pathophysiological process. New insights into the aging heart, including hormonal controls and specific molecular pathways, such as microRNAs, are pointing to myocardial aging as a potentially reversible process. While the overall process of aging remains mysterious, understanding the molecular pathways of myocardial aging has never been more important. Unraveling these pathways could lead to new therapies for the enormous and growing problem of HFpEF.

Citing Articles

The interplay of senescence and MMPs in myocardial infarction: implications for cardiac aging and therapeutics.

Balaraman A, Altamimi A, Babu M, Goyal K, Padmapriya G, Bansal P Biogerontology. 2025; 26(1):46.

PMID: 39832057 DOI: 10.1007/s10522-025-10190-6.

Mechanistic Relevance of Ventricular Arrhythmias in Heart Failure with Preserved Ejection Fraction.

Bahrami P, Aromolaran K, Aromolaran A Int J Mol Sci. 2025; 25(24.

PMID: 39769189 PMC: 11677834. DOI: 10.3390/ijms252413423.

Evaluation of Galectin-3 in Dogs with Atrial Fibrillation.

Arcuri G, Valente C, Romito G, Bonsembiante F, Mazzoldi C, Contiero B Animals (Basel). 2024; 14(17).

PMID: 39272333 PMC: 11394297. DOI: 10.3390/ani14172547.

The Concept of "Heart Failure with Preserved Ejection Fraction": Time for a Critical Reappraisal.

Fragasso G Rev Cardiovasc Med. 2024; 24(7):202.

PMID: 39076999 PMC: 11266467. DOI: 10.31083/j.rcm2407202.

Empagliflozin protects against heart failure with preserved ejection fraction partly by inhibiting the senescence-associated STAT1-STING axis.

Shi Y, Zhao L, Wang J, Liu X, Bai Y, Cong H Cardiovasc Diabetol. 2024; 23(1):269.

PMID: 39044275 PMC: 11267814. DOI: 10.1186/s12933-024-02366-0.

References

Collier P, Watson C, Voon V, Phelan D, Jan A, Mak G . Can emerging biomarkers of myocardial remodelling identify asymptomatic hypertensive patients at risk for diastolic dysfunction and diastolic heart failure?. Eur J Heart Fail. 2011; 13(10):1087-95. DOI: 10.1093/eurjhf/hfr079. View

Csiszar A, Labinskyy N, Smith K, Rivera A, Orosz Z, Ungvari Z . Vasculoprotective effects of anti-tumor necrosis factor-alpha treatment in aging. Am J Pathol. 2007; 170(1):388-98. PMC: 1762698. DOI: 10.2353/ajpath.2007.060708. View

Schriner S, Linford N, Martin G, Treuting P, Ogburn C, Emond M . Extension of murine life span by overexpression of catalase targeted to mitochondria. Science. 2005; 308(5730):1909-11. DOI: 10.1126/science.1106653. View

Misaka T, Suzuki S, Miyata M, Kobayashi A, Ishigami A, Shishido T . Senescence marker protein 30 inhibits angiotensin II-induced cardiac hypertrophy and diastolic dysfunction. Biochem Biophys Res Commun. 2013; 439(1):142-7. DOI: 10.1016/j.bbrc.2013.08.002. View

Dannenberg A, Levy D, Garrison R . Impact of age on echocardiographic left ventricular mass in a healthy population (the Framingham Study). Am J Cardiol. 1989; 64(16):1066-8. DOI: 10.1016/0002-9149(89)90816-3. View

Planavila A, Iglesias R, Giralt M, Villarroya F . Sirt1 acts in association with PPARα to protect the heart from hypertrophy, metabolic dysregulation, and inflammation. Cardiovasc Res. 2010; 90(2):276-84. DOI: 10.1093/cvr/cvq376. View

Sundaresan N, Pillai V, Wolfgeher D, Samant S, Vasudevan P, Parekh V . The deacetylase SIRT1 promotes membrane localization and activation of Akt and PDK1 during tumorigenesis and cardiac hypertrophy. Sci Signal. 2011; 4(182):ra46. DOI: 10.1126/scisignal.2001465. View

Colman R, Anderson R, Johnson S, Kastman E, Kosmatka K, Beasley T . Caloric restriction delays disease onset and mortality in rhesus monkeys. Science. 2009; 325(5937):201-4. PMC: 2812811. DOI: 10.1126/science.1173635. View

Senyo S, Steinhauser M, Pizzimenti C, Yang V, Cai L, Wang M . Mammalian heart renewal by pre-existing cardiomyocytes. Nature. 2012; 493(7432):433-6. PMC: 3548046. DOI: 10.1038/nature11682. View

10.

Bruunsgaard H, Skinhoj P, Pedersen A, Schroll M, Pedersen B . Ageing, tumour necrosis factor-alpha (TNF-alpha) and atherosclerosis. Clin Exp Immunol. 2000; 121(2):255-60. PMC: 1905691. DOI: 10.1046/j.1365-2249.2000.01281.x. View

11.

van Almen G, Verhesen W, van Leeuwen R, van de Vrie M, Eurlings C, Schellings M . MicroRNA-18 and microRNA-19 regulate CTGF and TSP-1 expression in age-related heart failure. Aging Cell. 2011; 10(5):769-79. PMC: 3193380. DOI: 10.1111/j.1474-9726.2011.00714.x. View

12.

Crow M . Sir-viving cardiac stress: cardioprotection mediated by a longevity gene. Circ Res. 2004; 95(10):953-6. DOI: 10.1161/01.RES.0000148666.20729.1c. View

13.

Miles E, Rees D, Banerjee T, Cazzola R, Lewis S, Wood R . Age-related increases in circulating inflammatory markers in men are independent of BMI, blood pressure and blood lipid concentrations. Atherosclerosis. 2006; 196(1):298-305. DOI: 10.1016/j.atherosclerosis.2006.11.002. View

14.

Taneike M, Yamaguchi O, Nakai A, Hikoso S, Takeda T, Mizote I . Inhibition of autophagy in the heart induces age-related cardiomyopathy. Autophagy. 2010; 6(5):600-6. DOI: 10.4161/auto.6.5.11947. View

15.

Hamdani N, Krysiak J, Kreusser M, Neef S, Dos Remedios C, Maier L . Crucial role for Ca2(+)/calmodulin-dependent protein kinase-II in regulating diastolic stress of normal and failing hearts via titin phosphorylation. Circ Res. 2013; 112(4):664-74. DOI: 10.1161/CIRCRESAHA.111.300105. View

16.

Hamdani N, Bishu K, von Frieling-Salewsky M, Redfield M, Linke W . Deranged myofilament phosphorylation and function in experimental heart failure with preserved ejection fraction. Cardiovasc Res. 2012; 97(3):464-71. DOI: 10.1093/cvr/cvs353. View

17.

Movsesian M, Karimi M, Green K, Jones L . Ca(2+)-transporting ATPase, phospholamban, and calsequestrin levels in nonfailing and failing human myocardium. Circulation. 1994; 90(2):653-7. DOI: 10.1161/01.cir.90.2.653. View

18.

Xu A, Narayanan N . Effects of aging on sarcoplasmic reticulum Ca2+-cycling proteins and their phosphorylation in rat myocardium. Am J Physiol. 1998; 275(6):H2087-94. DOI: 10.1152/ajpheart.1998.275.6.H2087. View

19.

Inuzuka Y, Okuda J, Kawashima T, Kato T, Niizuma S, Tamaki Y . Suppression of phosphoinositide 3-kinase prevents cardiac aging in mice. Circulation. 2009; 120(17):1695-703. DOI: 10.1161/CIRCULATIONAHA.109.871137. View

20.

Chen C, Nakayama M, Nevo E, Fetics B, Maughan W, Kass D . Coupled systolic-ventricular and vascular stiffening with age: implications for pressure regulation and cardiac reserve in the elderly. J Am Coll Cardiol. 1998; 32(5):1221-7. DOI: 10.1016/s0735-1097(98)00374-x. View